Show Notes
Description: Listen as co-hosts Jackie Lee and Josh Hammerquist speak to data scientist Supriya Ramachandra as they discuss how she attacks messy data with Artificial Intelligence and Machine Learning. From this discussion, actuaries will learn about how these cutting-edge tools can be used in their work. PleaseNote: At timestamp 11:00: The training data was created through manual annotation — it took 4 annotators about a week to label the clinical notes. At timestamp 12:24–12:26, we said "non-supervised" — the correct term is "unsupervised learning."
More from SOA Podcasts - Society of Actuaries
Host Danny Moore, FSA, MAAA, CERA and guests John Nolan and Marc Marion from Octaviant Financial discuss the challenges of specialized high-cost drug treatments, their efficacy, and potential vehicles to manage the unique risks involved with these treatments.
The Young Professional Advisory Council's Justin Le speaks with Gouri Kumaran, AVP at Kuvare, about her challenges and triumphs as a career changer into the actuarial profession and her experiences along the way.
In this episode, host Ankit Nanda, FSA, MAAA, FCA, speaks with Dr. Mei Sum Chan, Head of Medical Analytics, R&D at Pacific Life Re, about the science of biological aging and what it means for actuaries. The conversation covers how biomarkers of aging are measured, what real-world data can (and cannot) tell us about health and longevity, and how these developments are beginning to shape actuarial work in health and longevity risk.
The Young Professional Advisory Council's Adam Krompiewski speaks with Cristi-Alice Danielson, Director of Individual Products & Pricing at Wawanesa Insurance, about building a unique actuarial career with a smaller company in Winnipeg, Manitoba, and the lessons she has learned along the way.
Host Ankit Nanda, FSA, MAAA, FCA, speaks with Paul Skrtich, ASA, MAAA, ACIA, Senior Vice President, Accident and Health at OdysseyRe, about how health insurance looks from the reinsurer's seat, where the tail of the claims distribution drives the economics. The conversation covers lasers on known high-cost claimants, emerging cost drivers from skin substitutes to GLP-1s and cell and gene therapies, and how ACOs and provider-payer alignment of interests reshape the risk reaching the excess layers.